Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Cash from Operations (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Cash from Operations for 15 consecutive years, with 1840000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 24.65% to 1840000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 5517000.0, a 15.68% increase, with the full-year FY2024 number at 5183000.0, down 21.64% from a year prior.
  • Cash from Operations was 1840000.0 for Q3 2025 at NovaBay Pharmaceuticals, up from 2991000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 638000.0 in Q4 2024 to a low of 4318000.0 in Q4 2021.
  • A 5-year average of 1655000.0 and a median of 1689000.0 in 2022 define the central range for Cash from Operations.
  • Biggest YoY gain for Cash from Operations was 188.37% in 2024; the steepest drop was 278.02% in 2024.
  • NovaBay Pharmaceuticals' Cash from Operations stood at 4318000.0 in 2021, then soared by 72.0% to 1209000.0 in 2022, then surged by 40.28% to 722000.0 in 2023, then soared by 188.37% to 638000.0 in 2024, then tumbled by 388.4% to 1840000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Cash from Operations are 1840000.0 (Q3 2025), 2991000.0 (Q2 2025), and 1324000.0 (Q1 2025).